Ascentage Pharma Group International announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation (the public notice period of which ended on July 18, 2022) to a new drug application (NDA) that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) who are resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.66 HKD | -1.19% | -8.16% | -38.97% |
Apr. 09 | Ascentage Pharma Chairman Boosts Stake in Firm | MT |
Apr. 04 | Ascentage Pharma Group Directors Acquire Company Shares | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.97% | 613M | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- 6855 Stock
- News Ascentage Pharma Group International
- Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML